AbbVie Inc. (NYSE:ABBV) [Trend Analysis] regains street interests, as shares shows upbeat performance moved up 1.90% on Tuesday and it traded at $63.70. The 52-week high of the share price is -8.40% and 52-week low of the share price is 42.99%.
AbbVie (NYSE: ABBV) announced the U.S. Food and Drug Administration (FDA) updated the IMBRUVICA Prescribing Information (PI) to include new data from two Phase 3 trials supporting its expanded use in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The label now includes overall survival (OS) results in previously-untreated CLL/SLL patients from the Phase 3 RESONATETM-2 (PCYC-1115) trial.
The IMBRUVICA label has also been updated with safety and efficacy data from the Phase 3 HELIOS (CLL3001) trial assessing the use of IMBRUVICA in combination with bendamustine and rituximab (BR) versus placebo plus BR in relapsed/refractory patients with CLL/SLL. As well, following a review of the November 2015 supplemental New Drug Application (sNDA), the FDA has approved a new IMBRUVICA indication to include the treatment of patients with SLL with or without the deletion of chromosome 17p (del 17p).1 IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
Moving toward technical analysis, the current ratio, or the liquidity ratio of a company was calculated 1.60 as compared to its debt to equity ratio stands at 6.87. This is an important indicator as a higher ratio typically suggests that investors are investing more confidently as compared to companies in the same industry has lower ratios. When calculating in the EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at 185.20%. Investors looking further ahead will note that the Price to next year’s EPS is 19.41%.
Noting a main crunch of analyst research by WSJ, ABBV under observation of quarterly per share earnings, it has second quarter 2016 trend of $1.20, while in next quarter estimated EPS trend is $1.22 and for annual basis for 2016 estimated EPS is $4.80.
Relatively pool of WSJ analyst issues diverse rating, as for current level it has 14 experts rated as “BUY” security, 1 analyst recommend as “Overweight,” and 6 experts rated as “Hold”.
As for as concerns shares volumes, in share capital AbbVie Inc. (NYSE:ABBV) has 1613.34 million outstanding shares among them 1604.62 million shares have been floated in market exchange. The firm’s institutional ownership remained 72.80% while insider ownership included 0.10%.
The stock showed weekly upbeat performance of 3.68%, which maintained for the month at 9.99%. Likewise the positive performance for the quarter recorded as 21.60% and for the year was 1.28%, while the YTD performance remained at 9.70%.